Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
BIOSECURE Act
Pharma
Licensing deals, AI pact and Novo vs. KBP—Fierce Pharma Asia
Dianthus and Boehringer headlined the latest round of licensing deals featuring China biotechs. Takeda inked its second pact with Nabla Bio. And more.
Eric Sagonowsky
Oct 17, 2025 9:40am
Senate backs China competition amendment in defense bill
Oct 10, 2025 10:56am
WuXi Bio, WuXi XDC upbeat on 2025 after strong 2024 earnings
Mar 25, 2025 10:45am
WuXi AppTec offers rosy 2025 guidance despite US-China tensions
Mar 18, 2025 4:30pm
Trump investment policy could hit US-China biotech dealmaking
Feb 28, 2025 2:45pm
Should BeiGene or Legend sell itself in 2025?
Jan 9, 2025 9:15am
